TOH edition: Tuesday, 29 September 2026 · Health & Medicine
A Heart Drug Discovery Hiding in Plain Sight: Semaglutide Cut Major Cardiovascular Events by 20%
Reported by News-Medical.Net
Publisher date:
In adults with overweight or obesity and established cardiovascular disease without diabetes, semaglutide reduced major adverse cardiovascular events by 20%. Researchers continue to investigate the exact biological mechanisms behind the outcome.
A treatment already widely used for weight management has also shown a substantial reduction in major cardiovascular events among people with established heart disease but without diabetes, opening another line of inquiry into how cardiovascular risk can be reduced.
Read the original report at News-Medical.Net (opens in a new tab) →
Read the full front page of Tuesday, 29 September 2026 →
Get tomorrow's front page
Five reasons to believe in progress, delivered once a day.